We recently published a list of 10 Safest Dividend Stocks in the UK. In this article, we are going to take a look at where ...

AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...

In a report released today, Matthew Weston from UBS upgraded AstraZeneca (AZN – Research Report) to a Buy, with a price target of £142.00. The ...

Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () (NasdaqGS:AZN) from Neutral to Buy. Analyst Price Forecast Suggests 13.43% Upside As of ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

AstraZeneca’s fourth-quarter results were mixed, as it missed estimates for earnings but beat the same for sales. Core earnings of $2.09 per share rose 49%year over year at CER, while revenues ...

Lilly beat fourth-quarter estimates for earnings as well as sales. Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound, missed estimates, while that of non-incretin drugs like ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...